Objective An organic layer prepared from the cortex of Morus alba (Moraceae) was studied in order to identify the active compounds for heparinase. Methods Bioassay-guided fractionation resulted in the isolation of sanggenon G Results The compound showed inhibitory activity with IC50 of 3.7 μmol/L on heparinase in vitro as well as 24 μmol/L in invasion assay using MDA-MB231 cells. Sanggenon G also had the moderate cytotoxicity at SW 620 (colon) and ACHN (kidney) cancer cell lines with IC50 of 10.96 and 13.44 μmol/L, respectively. Conclusion This is the first time that prenylated flavonoid sanggenon G is described as heparinase inhibitor. Besides, this flavonoid would be expected to be a metastasis inhibitor of cancer cells and also a valuable reagent to explore the mechanism of heparinase/heparanase-mediated metastasis.

Recent studies have shown that coronavirus disease-2019 (COVID-19) infection increased risk of stroke. Significant differences have been identified between the general population and COVID-19 stroke patients. There are unusual patterns of stroke occurred in COVID-19 patient are reported. Pathophysiologic theories about the relationship of COVID-19 infection and stroke are being published. Herein we report a rare case of stroke in a young COVID-19 patient, considered to be the result of vasculitis, and vessel changes that might have been caused by vasospasm based on serial brain imaging follow-up data. And we interpret this case based on pathophysiological characteristics of the severe acute respiratory syndrome coronavirus 2.